$52.10
0.42% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
GB00BYMT0J19
Symbol
LIVN

Livanova PLC Stock price

$52.10
-1.57 2.93% 1M
-11.10 17.56% 6M
+0.36 0.70% YTD
+3.97 8.25% 1Y
-32.71 38.57% 3Y
-26.16 33.43% 5Y
-0.87 1.64% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.22 0.42%
ISIN
GB00BYMT0J19
Symbol
LIVN
Sector

Key metrics

Market capitalization $2.83b
Enterprise Value $2.84b
P/E (TTM) P/E ratio 122.24
EV/FCF (TTM) EV/FCF 26.16
EV/Sales (TTM) EV/Sales 2.30
P/S ratio (TTM) P/S ratio 2.29
P/B ratio (TTM) P/B ratio 2.16
Revenue growth (TTM) Revenue growth 10.69%
Revenue (TTM) Revenue $1.24b
EBIT (operating result TTM) EBIT $137.27m
Free Cash Flow (TTM) Free Cash Flow $108.67m
Cash position $666.58m
EPS (TTM) EPS $0.43
P/E forward 93.43
P/S forward 2.26
EV/Sales forward 2.27
Short interest 4.82%
Show more

Is Livanova PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Livanova PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

Buy
89%
Hold
11%

Financial data from Livanova PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,238 1,238
11% 11%
100%
- Direct Costs 394 394
12% 12%
32%
844 844
10% 10%
68%
- Selling and Administrative Expenses 471 471
6% 6%
38%
- Research and Development Expense 181 181
2% 2%
15%
192 192
34% 34%
15%
- Depreciation and Amortization 54 54
9% 9%
4%
EBIT (Operating Income) EBIT 137 137
66% 66%
11%
Net Profit 24 24
720% 720%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Livanova PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Livanova PLC Stock News

Neutral
Business Wire
4 days ago
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
Neutral
Seeking Alpha
16 days ago
LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldm...
Neutral
Business Wire
17 days ago
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.
More Livanova PLC News

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Vladimir Makatsaria
Employees 2,900
Founded 1987
Website www.livanova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today